Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06830629 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
A Phase 2 study of Proteinuric Kidney Disease, sponsored by Maze Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 20
- Study locations
NCT06830629 is a Phase 2 study of Proteinuric Kidney Disease that is actively recruiting participants, run by Maze Therapeutics. The registered enrollment target is 56 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT06830629, a Phase 2 study of Proteinuric Kidney Disease, is actively recruiting participants, sponsored by Maze Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
Conditions Studied
Interventions
- DRUG MZE829
Study Locations (20)
Florida
- Research Site - Atlantis
- Research Site - Brandon
- Research Site - Brooksville
- Research Site - Hollywood
- Research Site - Melbourne
- Research Site - Miami Lakes
- Research Site - Orlando
Georgia
- Research Site - College Park
- Research Site - Cordele
- Research Site - Macon
- Research Site - Riverdale
- Research Site - Savannah
Alabama
- Research Site - Decatur
- Research Site - Huntsville
- Research Site - Montgomery
California
- Research Site - Granada Hills
Connecticut
- Research Site - Bloomfield
Illinois
- Research Site - Chicago
Kansas
- Research Site - Kansas City
Kentucky
- Research Site - Bowling Green
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-02-05 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06830629
The ClinicalTrials.gov registry entry for NCT06830629 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Maze Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Proteinuric Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which MZE829 is the first listed.
NCT06830629 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, Georgia, Alabama.
Frequently Asked Questions
What is clinical trial NCT06830629 about?
NCT06830629 is a clinical study titled "A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease". This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
What is the current status of trial NCT06830629?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2025-02-05. Estimated completion is 2026-09.
What conditions does trial NCT06830629 study?
This clinical trial studies the following conditions: Proteinuric Kidney Disease.
What interventions are being tested in trial NCT06830629?
The interventions under investigation include: MZE829 (DRUG).
Who is sponsoring clinical trial NCT06830629?
This trial is sponsored by Maze Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06830629 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Proteinuric Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.